An unusual adverse effect of nadroparin injections: Calcinosis cutis

Nuño-González, Almudena; Calzado-Villarreal, Leticia; Gutiérrez-Pascual, M.; Villegas, Reyes Gamo; Sanz-Robles, Henar; Sánchez-Gilo, A.; Moraleda, Fernando Pinedo; López‐Estebaranz, José Luis

doi:10.5070/d37m82j26d

Cited by 3 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is thus important to determine whether the synthesis of homogeneous LMWH can be scaled to meet the needs of the current anticoagulant market. ,,,, …”

Section: Polyanions That Inhibit Blood Coagulationmentioning

confidence: 99%

Targeting Biological Polyanions in Blood: Strategies toward the Design of Therapeutics

Takeuchi

Abbina

et al. 2020

Biomacromolecules

View full text Add to dashboard Cite

In this Review, we highlight well-described and emerging polyanions, and the way these molecules can be targeted in the design of potential therapeutics (synthetic and biologics) with applications in thrombosis and hemostasis. It is important to strike a balance between bleeding and clotting. In thrombosis, unwanted blood clots are formed in the lumen of a blood vessel, obstructing the flow of blood through the circulatory system. Over many years of research, several polyanionic biopolymers that can either impede (anticoagulant) or promote (procoagulant) blood clotting have been identified. Mediators impeding blood clotting, including polyanionic polysaccharides such as heparins and heparin mimics, are widely used as antithrombotics, although they impart adverse complications such as bleeding. Emerging synthetic polycations and well-described cationic proteins that are specifically designed to neutralize the biological activity of heparins to prevent bleeding complications are discussed. On the other hand, there is growing evidence that several polyanions bear a procoagulant nature in blood; polyphosphate (polyP), neutrophil extracellular traps (NETs), extracellular RNA, and cell-free DNA are shown to promote blood clotting. Recent research highlights the use of polycations and enzymes that either inhibit or cleave these procoagulant polyanions and demonstrates the proof-of-concept design of new antithrombotics without bleeding side effects. Additional studies have shown that some of these procoagulant polyanions can be used as a hemostat to prevent bleeding in an emergency. There are significant opportunities for chemists in the design of new inhibitors and agents with improved selectivity toward these biological polyanions, furthering the development of novel therapeutics.

show abstract

“…It is thus important to determine whether the synthesis of homogeneous LMWH can be scaled to meet the needs of the current anticoagulant market. ,,,, …”

Section: Polyanions That Inhibit Blood Coagulationmentioning

confidence: 99%

Targeting Biological Polyanions in Blood: Strategies toward the Design of Therapeutics

Takeuchi

Abbina

et al. 2020

Biomacromolecules

View full text Add to dashboard Cite

show abstract

Extraosseous Calcification in End‐stage Renal Disease: From Visceral Organs to Vasculature

Molenaar

Reekum

Rookmaaker

et al. 2014

Seminars in Dialysis

View full text Add to dashboard Cite

In earlier days, periarticular accumulations of calcium phosphate causing tumor-like depositions were considered the result of passive precipitation and referred to as metastatic calcifications. From sophisticated computer tomographic studies and growing insight, we have learned that calcifications in the cardiovascular system are far more threatening and in fact one of the most important sequela of end-stage renal disease. The histologic characteristic of uremia-related calcification is arteriosclerosis of the media. In addition, there is atherosclerosis of the intima, due to the high prevalence of classic cardiovascular risk factors in renal disease. The two vascular features can frequently exist at different sites in the vasculature. Novel diagnostic techniques are helping to elucidate the pathogenetic mechanisms of active conversion of vascular smooth muscle cells to osteochondritic cells. Through this process, extensive calcification of the central and peripheral vasculature ensues, influenced by different promotors and inhibitors. Calciphylaxis is a special form of extraosseous calcification leading to skin necrosis. The factors that trigger the development of calciphylaxis are not completely understood, but this syndrome shares part of the pathophysiologic basis of extraosseous calcification in general. However, the therapeutic approach must be prompt and aggressive, because of the poor prognosis. Frequently, a fatal outcome cannot be avoided in calciphylaxis.

show abstract

Soft tissue calcium deposits

Chuah

Lee²

2017

Annals of Saudi Medicine

View full text Add to dashboard Cite

An unusual adverse effect of nadroparin injections: Calcinosis cutis

Cited by 3 publications

References 0 publications

Targeting Biological Polyanions in Blood: Strategies toward the Design of Therapeutics

Targeting Biological Polyanions in Blood: Strategies toward the Design of Therapeutics

Extraosseous Calcification in End‐stage Renal Disease: From Visceral Organs to Vasculature

Soft tissue calcium deposits

Contact Info

Product

Resources

About